Primary-document archive · Reviewed September 1, 2026
Start with the documents behind the claims
This archive connects the central official assessments, scientific papers, historical records, and analytical studies used throughout the NRS Phenibut reference. Each entry identifies what the source can establish, what remains uncertain, and where the original record can be inspected.
Many precise Phenibut claims are repeated through chains of secondary reviews. A repeated citation is not independent confirmation. Readers need the original study, methods, model, population, and uncertainty before treating a claim as established.
Official document desk
Phenibut Pre-Review Report
The detailed 44th ECDD technical review covering identification, pharmacology, toxicology, dependence, adverse events, surveillance, markets, and Member State information.
44th ECDD Findings and Recommendation
The committee’s concise assessment and recommendation that Phenibut should not proceed to critical review at that time and should remain under surveillance.
Substances Under Surveillance
The surveillance list updated March 24, 2025 confirms Phenibut’s continued status and summarizes the limited evidence concerning withdrawal, abuse liability, and magnitude of misuse.
ECDD Information Repository
WHO’s open repository preserves review reports, recommendations, scheduling context, and technical information for substances considered by the Expert Committee.
Federal Register Notice
The United States notice communicating international scheduling activity following the 44th ECDD cycle. It should be read as a procedural record, not as FDA approval or a domestic legality determination.
Current Poisons Standard
The in-force Australian instrument lists Phenibut in Schedule 9 and identifies the free base, hydrochloride, and hydrobromide forms.
How to read the WHO decision
A pre-review asks whether available information justifies a later critical review. It is not a declaration of efficacy, safety, approval, or legality.
→
The committee found the available information too limited to justify that next step at the time.
→
WHO continues monitoring new information. Individual countries may impose controls independently.
WHO’s recommendation emphasized limited information on withdrawal, abuse liability, magnitude of misuse, and similarity to internationally controlled substances. The committee also recognized therapeutic use in a small number of countries. These points explain the surveillance outcome; they do not make commercial supply lawful worldwide.
What WHO found about evidence quality
Modern appraisal is constrained
Randomized controlled trials were not available to WHO. Much of the older clinical literature was inaccessible, difficult to retrieve, or available only through secondary descriptions.
Frequently repeated figures have weak provenance
WHO characterized pharmacokinetic information as limited and could not verify the primary basis for several exact figures repeated in later sources.
Important questions remain untested
The committee reported no controlled animal or human studies directly examining Phenibut abuse potential and no animal studies examining dependence potential.
Preclinical evidence is extremely narrow
The nootropic narrative relies heavily on descriptions of an inaccessible Russian-language mouse study, not a modern controlled human evidence program.
The secondary-citation problem
Lapin’s 2001 review remains a major citation trunk for later Phenibut summaries. WHO attempted to trace claims concerning pharmacokinetics, toxicology, therapeutic index, receptor activity, and clinical effects through the cited literature. In several instances the underlying primary source was absent, unavailable, or did not clearly support the way the claim was later repeated.
This does not prove that every inherited claim is false. It means the confidence should remain limited until the primary experiment can be inspected or independently replicated. See the pharmacokinetic source-quality analysis.
Historical record and confidence labels
Early synthesis publication
Perekalin and Sopova’s Russian-language paper on γ-amino-acid derivatives is cited as the early synthesis record. The underlying chemistry predates the frequently repeated “developed in the 1960s” shorthand.
Khaunina and Maslova pharmacology
WHO cites Russian-language work concerning brain penetration and pharmacological effects in animal models. Independent English-language appraisal remains limited.
Soviet medicine registration
Russian historical sources identify a December 18, 1974 Ministry of Health order as the formal State Register milestone.
Latvian SSR State Prize
A state prize recognized work on synthesis, pharmacology, clinical use, industrial production, and introduction of Phenibut into practice.
General link stronger than mission-specific lore
Involvement of Soviet space-medicine researchers supports a general connection. A specific Apollo–Soyuz use claim remains insufficiently verified and should not be presented as settled fact.
Russian and Eastern European source corpus
The Russian-language record is foundational but fragmented. This catalog separates sources that can be inspected directly from historical citations that have only been recovered through later bibliographies. A listing here confirms that a record was identified; it does not validate the paper’s methods, reported findings, or modern clinical relevance.
Direct source means a journal, registry, manufacturer, or repository record can be opened. Secondary access means the citation is visible through a later review or bibliographic database. Retrieval target means the original has not yet been obtained and independently appraised. Russian and Soviet records are not treated as equivalent to modern controlled evidence.
Core historical gateway
Lapin: Phenibut (β-Phenyl-GABA)
I. P. Lapin’s review is the principal digitized gateway to more than 300 mostly Russian and Soviet references. It is a secondary narrative source, not a substitute for the underlying experiments.
Modern human-study and registry records
О биоэквивалентности анвифена и фенибута
English: “On the bioequivalence of Anvifen and Phenibut.” An open randomized crossover pharmacokinetic study in 18 healthy volunteers. This is a small bioequivalence study, not an efficacy trial.
- Journal
- Экспериментальная и клиническая фармакология
- DOI
- 10.30906/0869-2092-2011-74-5-43-44
Функциональные исходы перинатального поражения нервной системы у детей и пути их коррекции
English: “Functional outcomes of perinatal nervous-system injury in children and approaches to their correction.” A randomized pediatric comparison involving 87 children. The unusual comparator, limited blinding information, and reported endpoints require careful appraisal.
- Population
- 87 children; Phenibut group n=44
- Evidence
- Comparative human study
Особенности влияния фенибута на параметры системного кровообращения
English: “Features of Phenibut’s effects on systemic circulation and mechanisms maintaining arterial pressure.” A small hemodynamic study in 27 young swimmers; its size, population, and endpoints limit generalization.
- Journal
- Вестник Волгоградского государственного медицинского университета
- Design
- Small pediatric physiology study
Фармакологическая коррекция нейрогенной дисфункции нижних мочевых путей у детей
English: “Pharmacological correction of neurogenic lower urinary-tract dysfunction in children.” Twenty-four children received a multi-component intervention, so Phenibut’s independent contribution cannot be isolated.
- Journal
- Здоров’я дитини, 15(3)
- DOI
- 10.22141/2224-0551.15.3.2020.204550
Noofen observational study
A non-interventional study followed 90 patients in Latvian general practices. With no randomized untreated or placebo control, the report is vulnerable to expectation, selection, and regression-to-the-mean effects.
- PMID
- 40807194
- Evidence
- Observational human study
BE-FNB01-25 comparative pharmacokinetics protocol
The registry describes an open randomized crossover comparison of Russian and Latvian Phenibut products in healthy volunteers. A protocol record does not establish a result; no completed outcome was available in the retrieved entry.
- Protocol
- BE-FNB01-25
- Planned enrollment
- 40
Medicinal-product and official registry documents
These records establish how products are described or registered in their home jurisdictions. Manufacturer information and prescribing documents are not independent evidence of efficacy, and their human-use instructions are not reproduced here.
Anvifen manufacturer record
Sotex identifies Anvifen as prescription aminophenylbutyric-acid capsules and provides Russian professional and patient documents.
Phenibut–Vertex record
Vertex’s official product page identifies the prescription tablet product and links its current Russian patient information.
State Register portal
The Ministry of Health portal is the authoritative starting point for current registration and clinical-trial records. Entries can change and should be archived with a retrieval date.
Phenibut-LF product characteristic
Lekpharm publishes a Belarusian manufacturer record and downloadable professional product characteristic. It is regulatory/manufacturer documentation, not an independent clinical study.
Noofen product characteristic
The Latvian record identifies Phenibutum as the active substance and preserves product information for two capsule presentations. The archive links the source without reproducing administration instructions.
Historical Soviet and Russian bibliography
The following 22 citations were identified through Lapin’s reference network. They are cataloged as retrieval targets unless a direct database record is linked. Exact-title discovery links are provided so researchers can continue the search through libraries, RSCI/eLIBRARY, institutional collections, and citation chaining.
| Year | Original or translated citation target | Record type | Access |
|---|---|---|---|
| 1964 | Khaunina RA. Tranquillizing effects of β-phenyl-γ-aminobutyric acid (“Phenigama”). Byull Eksp Biol Med 1:54–58. | Early pharmacology | Exact-title search |
| 1964 | Lapin IP, Khaunina RA. Pharmacology and clinical use of GABA and its derivatives. In: Role of GABA in the Activity of the Nervous System, Leningrad. | Monograph chapter | Exact-title search |
| 1965 | Maslova MN, Khaunina RA. Distribution of β-phenyl-γ-aminobutyric acid in the body and certain indices of its central effects. Byull Eksp Biol Med 8:65–69. | Distribution study | Exact-title search |
| 1967 | Maslova MN, Khaunina RA. Penetration of GABA and its phenyl derivative into the brain and pharmacological effects during ontogenesis. Evol Neirofiziol Neirokhim 5:186–191. | CNS distribution | Exact-title search |
| 1967 | Stark MB et al. Electrophysiological study of the central effects of GABA and Phenibut. | Electrophysiology | Citation search |
| 1968 | Khaunina RA. Structure–activity relationships among phenyl derivatives of GABA. Farmakol Toksikol 2:202–205. | Medicinal chemistry | PubMed search |
| 1969 | Khaunina RA, Prakhie IB. Effect of Phenibut on anticonvulsants. | Pharmacology | Citation search |
| 1971 | Khaunina RA. Pharmacological activity of optical isomers of β-phenyl-γ-aminobutyric acid. Byull Eksp Biol Med 11:49–51. | Stereopharmacology | PubMed search |
| 1975 | Kovalev GV, Morozov IS. Phenibut and neural vasomotor mechanisms. Sixth International Congress of Pharmacology. | Conference abstract | Citation search |
| 1979 | Allikmets LH et al. Dopaminergic component of Phenibut action. | Pharmacology | Citation search |
| 1979 | Kovalev GV, ed. Pharmacology and Clinic of GABA and Its Analogs. Volgograd. | Monograph/proceedings | Exact-title search |
| 1980 | Kozlovskaya et al. Comparison of psychotropic and neurochemical action of Phenibut. | Pharmacology | Citation search |
| 1981 | All-Union Symposium: Phenibut and Derivatives of GABA and α-Pyrrolidones (Clinic, Pharmacology, Chemistry, Industry). Cherkassy. | Conference proceedings | Exact-title search |
| 1982 | Rago LK et al. Binding of Phenibut to bicuculline-insensitive GABA receptors. | Receptor pharmacology | Citation search |
| 1982 | Kovalev GI et al. Presynaptic component in the mechanism of Phenibut. | Pharmacology | Citation search |
| 1984 | Lapin IP. Phenibut and baclofen as antagonists of phenylethylamine. Trudy Tartu Gos Univ 687:36–44. | Mechanistic pharmacology | Exact-title search |
| 1985 | Lapin IP. Dissimilarities and similarities between Phenibut, baclofen, and diazepam in interaction with phenylethylamine. Farmakol Toksikol 48:50–54. | Comparative pharmacology | PubMed search |
| 1986 | Goldblat YuV, Lapin IP. Potentiation of the therapeutic effect of antiparkinsonian drugs by Phenibut. Zh Nevropatol Psikhiatrii 86:1146–1148. | Clinical/pharmacologic | PubMed search |
| 1989 | Khaunina RA, Lapin IP. Use of Phenibut in psychoneurology and its place among other psychotropic drugs. Zh Nevropatol Psikhiatrii 89:142–151. | Clinical review | PubMed search |
| 1990 | Mehilane LS, Rago LK, Allikmets LH. Pharmacology and Clinic of Phenibut. Tartu: Tartu State University. | Estonian/Soviet monograph | Exact-title search |
| 1995 | Lapin IP et al. Phenibut and baclofen in affective disorders in alcoholic patients. Alcohol and Alcoholism 30:549. | Conference report | Citation search |
| 2000 | Belozertseva IV, Andreev BV. GABA-positive agents in morphine dependence and cessation. | Dependence pharmacology | Citation search |
Recent Russian-language preclinical and mechanistic records
Влияние фенибута на межполушарное взаимодействие мозга крыс
English: “Effect of Phenibut on interhemispheric transmission in the rat brain.” This is a rat electrophysiology study and cannot establish human efficacy or safety.
- PMID
- 19334513
- DOI
- 10.30906/0869-2092-2009-72-1-57-59
Phenibut compositions in focal cerebral ischemia
A Russian study compared Phenibut-containing organic-acid compositions in a rat occlusion model. It belongs in the preclinical library and does not support a human treatment claim.
- Model
- Rat focal cerebral ischemia
- Access
- Russian full text
Phenibut and GABAergic neurons after perinatal hypoxia
The paper examined GABAergic-neuron counts in rat neocortex after an experimental perinatal-hypoxia model. It is mechanistic animal evidence only.
- Journal
- Экспериментальная и клиническая фармакология 83(2):3–7
- DOI
- 10.30906/0869-2092-2020-83-2-3-7
Defensive conditioning and internal inhibition
A Russian-language rabbit-conditioning experiment indexed by PubMed. Its behavioral and physiologic observations are preclinical and should not be generalized to people.
- PMID
- 16756131
- Language
- Russian
Behavior and respiration in a negative-emotion model
A Russian-language rabbit study examining behavior and respiratory parameters under experimental stimuli. An English translation was later published separately.
- PMID
- 17944107
- English translation
- PMID 18607733
GABA-receptor agonists and learning
A rabbit conditioning study comparing GABA-receptor agonists. Its experimental learning model is not clinical efficacy evidence.
- PMID
- 19476215
- DOI
- 10.1017/S1138741600001438
eLIBRARY/RSCI, Russian State Library holdings, Soviet institute proceedings, and university collections remain essential for completing this archive. Automated discovery cannot establish that every historical record has been retrieved, deduplicated, translated, or methodologically reviewed.
Primary analytical and mechanistic studies
GC-MS can create misleading thermal products
Lee and colleagues showed that Phenibut can cyclize under thermal GC-MS conditions. Derivatization or carefully modified conditions were needed for reliable identification.
- PMID
- 28651175
- DOI
- 10.1016/j.forsciint.2017.06.002
F-Phenibut in mouse Purkinje cells
Irie and colleagues used in-vitro patch-clamp recordings to compare GABA-B agonists. The result is preclinical and does not establish human effects or safety.
- PMID
- 32735986
- DOI
- 10.1016/j.ejphar.2020.173437
Pooled-urine surveillance methodology
Archer and colleagues demonstrated longitudinal detection of new psychoactive substances using pooled urine and high-resolution mass spectrometry. It illustrates one route toward prevalence monitoring.
- PMID
- 32050035
- DOI
- 10.1111/bcp.14239
Online product composition
A 2024 analytical study of six online-purchased products reported mismatches between labeled and measured Phenibut content and found declared and undeclared additional ingredients.
- PMID
- 39459348
- Method
- HPLC-DAD and LC-MS
Research gaps identified by the primary record
- Accessible translation and independent appraisal of foundational Russian-language studies
- Modern, transparent human pharmacokinetic research with validated analytical methods
- Controlled abuse-liability and dependence studies rather than inference from case reports
- Population prevalence estimates using surveys, wastewater, pooled samples, and toxicology surveillance
- Comparative research on clinical management and a validated withdrawal-severity framework
- Independent replication of receptor, stereochemical, and cellular electrophysiology findings
- Longitudinal study of product identity, co-exposures, clinical outcomes, and recovery
Archive navigation
Archive scope
This page summarizes and links public records; it does not reproduce complete copyrighted articles. Historical claims are labeled according to source accessibility. Inclusion is not endorsement, medical advice, or human-use guidance. Readers should inspect the original source before relying on any technical conclusion.